We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn more.
Recombinant Human IL-34
Interleukin 34 (IL-34) was originally identified in humans, by large scale screening of secreted proteins; orthologs have also been found in chimpanzee, murine, rat and chicken. Human IL-34 is synthesized as a 242 amino acid (aa) precursor that contains a 20 aa signal sequence and a 222 aa mature chain. IL-34 is secreted as a homodimer and contains one potential N-glycosylation site. IL-34 increases proliferation of immune cells known as monocytes; it elicits its activity by binding the Colony Stimulating Factor 1 Receptor (CSF-1R). Expression of IL-34 is most abundant in the spleen and is expressed in many other tissues including the heart, brain, liver, kidney, thymus, intestine and lung. Human IL-34 contains a C-terminal 6x-polyhistidine (6xHis) tag.
Product images on the website are not representative of actual product, including, but not limited to differences in cap color, tube type, or label format.
Instructions
Centrifuge vial before opening. Suspend the product by gently pipetting the above recommended solution down the sides of the vial. DO NOT VORTEX. Allow several minutes for complete reconstitution. For prolonged storage, dilute to working aliquots in a 0.1% BSA solution, store at -80°C and avoid repeat freeze thaws.
Technical Specifications
Alternate Names | None |
Accession Number | NP_689669 |
Source | Genetically modified CHO cells |
Predicted Molecular Mass | Dimer, 26 kDa (228 aa) |
AA Sequence | NEPLEMWPLT QNEECTVTGF LRDKLQYRSR LQYMKHYFPI NYKISVPYEG VFRIANVTRLQRAQVSEREL RYLWVLVSLS ATESVQDVLL EGHPSWKYLQ EVETLLLNVQ QGLTDVEVSPKVESVLSLLN APGPNLKLVR PKALLDNCFR VMELLYCSCC KQSSVLNWQD CEVPSPQSCSPEPSLQYAAT QLYPPPPWSP SSPPHSTGSV RPVRAQGEGL LPHHHHHH |
Formulation | Lyophilized from a 0.2 µm filtered solution containing phosphate buffered saline (PBS) |
Product Reconstitution | Sterile water at 0.1 mg/mL (reconstitution at concentrations > 0.1 mg/mL may result in a precipitate) |
Country of Origin | USA |
Specification* | Method of Determination | Acceptance Criteria |
Purity | Reducing and Non-Reducing SDS PAGE | ≥ 95% |
Endotoxin | Kinetic LAL (50% confidence) | ≤ 0.1 EU/µg |
*Lot-specific values for the above specifications are supplied with each product on its corresponding COA. The values provided here are minimum expected values to pass internal requirements.